- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 16,007
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematological Malignancies
- Interventions
- C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Primary Systemic Amyloidosis, Light Chain Deposition Disease
- Interventions
- bortezomib, dexamethasone, melphalan, microarray analysis, flow cytometry, laboratory biomarker analysis, quality-of-life assessment
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 3 more
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Interventions
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2
- Biological · Drug
- Lead sponsor
- David Bartlett, MD
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypertension, Mild Cognitive Impairment
- Interventions
- Candesartan, Lisinopril
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Melphalan, Dexamethasone, Autologous Hematopoietic Cell Transplantation (HCT), Fosaprepitant
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Growth Hormone Deficiency
- Interventions
- growth hormone (Nutropin)
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Osteoarthritis, Knee
- Interventions
- Oxytocin
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Healthy, Menopause
- Interventions
- Dietary Supplement with Proprietary Herbal Extract Blend and GABA, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Olly, PBC
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Abatacept
- Drug
- Lead sponsor
- Arthritis Northwest PLLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Pancreatic Cancer
- Interventions
- Nivolumab + Cabiralizumab, Stereotactic Body Radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- New York, New York • Seattle, Washington
- Conditions
- Ovarian Cancer, Peritoneal Cancer
- Interventions
- pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Preeclampsia, Microvascular Function
- Interventions
- Acetylcholine, Endothelin-1
- Drug
- Lead sponsor
- Anna Stanhewicz, PhD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Metastatic Cancer, Multiple Myeloma, Parathyroid Neoplasms, Renal Cancer, Thyroid Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer
- Interventions
- denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 12
- States / cities
- Encinitas, California • New Haven, Connecticut • Salisbury, Maryland + 9 more
- Conditions
- Lymphoma, Leukemia
- Interventions
- Thymoglobulin, Total Lymphoid Irradiation, Peripheral Blood Stem Cell Infusion, Rituximab
- Drug · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hemophilia A
- Interventions
- Emicizumab, Factor VIII (FVIII)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more
- Conditions
- Cardiac Arrhythmia
- Interventions
- Oxytocin, Saline
- Drug · Other
- Lead sponsor
- William Whang
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Dietary Supplement: Dietary supplement: Protein intake
- Dietary Supplement
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 8 Years to 10 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- Placebo, Pregabalin, LY545694 21 mg, LY545694 49 mg, LY545694 105 mg
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 8
- States / cities
- Greenbrae, California • Tustin, California • DeLand, Florida + 5 more
- Conditions
- Alcoholism, Alcohol Related Disorders
- Interventions
- oxytocin, placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Heart Failure
- Interventions
- sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 887 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
- Conditions
- Advanced Cancers
- Interventions
- Satraplatin, Abraxane
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- denosumab, teriparatide, Zoledronic acid
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Congenital Heart Diseases, Aortic Valve Disorder
- Interventions
- Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride, Cefazolin 30 mg/kg body weight
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Palo Alto, California